Table 2.
Univariate and multivariate analyses of factors associated with the response rate to a PD‐1/PD‐L1 inhibitor
| Univariate | Multivariate | |||
|---|---|---|---|---|
| Variable | OR (95% CI) | P | OR (95% CI) | P |
| Age (years) | ||||
| < 55 | 1.0 | — | — | — |
| 55–70 | 1.74 (0.18–17.22) | 0.636 | — | — |
| ≥ 70 | 4.44 (0.42–46.55) | 0.213 | — | — |
| Gender | ||||
| Male | 1.0 | — | — | — |
| Female | 0.21 (0.02–1.80) | 0.251 | ||
| Smoking status | ||||
| Never | 1.0 | — | — | — |
| Former | 2.12 (0.41–10.88) | 0.367 | ||
| Current | 0.93 (0.16–5.42) | 0.939 | ||
| EGFR | ||||
| Wild type | 1.0 | — | — | — |
| Mutant | 0.76 (0.65–0.90) | 0.572 | ||
| PD‐L1 expression | ||||
| Unknown and < 1% | 1.0 | — | — | — |
| Low (1–49%) | 2.81 (0.39–20.46) | 0.307 | — | — |
| High (≥ 50%) | 2.65 (0.46–15.15) | 0.274 | — | — |
| Histology | ||||
| SqCC | 1.0 | — | — | — |
| Adeno | 0.54 (0.12–2.46) | 0.429 | — | — |
| Other | 0.45 (0.05–4.46) | 0.497 | — | — |
| Agent | ||||
| Atezolizumab, nivolumab | 1.0 | — | — | — |
| Pembrolizumab | 6.75 (1.29–35.42) | 0.024 | 14.73 (2.25–96.34) | 0.005 |
| Pleural or pericardial metastasis | ||||
| Yes | 1.0 | — | — | — |
| No | 12.22 (1.43–104.71) | 0.022 | 25.97 (2.54–265.61) | 0.006 |
Adeno, adenocarcinoma; CI, confidence interval; OR, odds ratio; SqCC, squamous cell carcinoma.